Hope S. Rugo, MD, on the Phase II FIRST Study

2014 San Antonio Breast Cancer Symposium
Tweet this page

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Advertisement

Advertisement



Advertisement